Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated morbidity and mortality. Here we focus on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate vaccine candidates based on different target antigens that afford protection against challenge with ancestral and recent influenza B viruses from both antigenic lineages. A pentavalent vaccine combining all tested antigens protects mice from morbidity at a very low dose of 50 ng per antigen after a single vaccination. These findings support the further advancement of nucleoside-modified mRNA-LNPs expressing multiple conserved antigens as universal influenza virus vaccine candidates.

信使 RNA (mRNA) 疫苗代表了一种新的、有效的疫苗平台，具有快速开发的高能力。产生具有引发持久、广泛交叉反应免疫反应的潜力的通用流感病毒疫苗是降低流感相关发病率和死亡率的必要条件。在这里，我们专注于开发基于脂质纳米颗粒包裹的核苷修饰mRNA（mRNA-LNP）平台的通用乙型流感病毒疫苗。我们评估了基于不同靶抗原的候选疫苗，这些靶抗原提供保护免受来自两个抗原谱系的祖先和最近的乙型流感病毒的攻击。结合所有测试抗原的五价疫苗可在单次疫苗接种后以每种抗原 50 ng 的极低剂量保护小鼠免于发病。